XVIP.Y logo

Xvivo Perfusion OTCPK:XVIP.Y Stock Report

Last Price

US$10.67

Market Cap

US$1.3b

7D

0%

1Y

n/a

Updated

23 Dec, 2024

Data

Company Financials +

Xvivo Perfusion AB (publ)

OTCPK:XVIP.Y Stock Report

Market Cap: US$1.3b

XVIP.Y Stock Overview

A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details

XVIP.Y fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Xvivo Perfusion AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Xvivo Perfusion
Historical stock prices
Current Share PriceSEK 10.67
52 Week HighSEK 12.97
52 Week LowSEK 7.34
Beta2.15
1 Month Change0%
3 Month Change-15.25%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO166.75%

Recent News & Updates

Recent updates

Shareholder Returns

XVIP.YUS Medical EquipmentUS Market
7D0%-1.2%-2.7%
1Yn/a10.0%23.4%

Return vs Industry: Insufficient data to determine how XVIP.Y performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how XVIP.Y performed against the US Market.

Price Volatility

Is XVIP.Y's price volatile compared to industry and market?
XVIP.Y volatility
XVIP.Y Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: XVIP.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine XVIP.Y's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998161Christoffer Rosenbladwww.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.

Xvivo Perfusion AB (publ) Fundamentals Summary

How do Xvivo Perfusion's earnings and revenue compare to its market cap?
XVIP.Y fundamental statistics
Market capUS$1.33b
Earnings (TTM)US$18.51m
Revenue (TTM)US$68.01m

71.9x

P/E Ratio

19.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XVIP.Y income statement (TTM)
RevenueSEK 750.59m
Cost of RevenueSEK 192.08m
Gross ProfitSEK 558.52m
Other ExpensesSEK 354.25m
EarningsSEK 204.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)6.48
Gross Margin74.41%
Net Profit Margin27.21%
Debt/Equity Ratio0%

How did XVIP.Y perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 19:38
End of Day Share Price 2024/11/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB